Global Insomnia Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Hospital, Retail, and Others), By Therapy Type (Pharmacological and Non-Pharmacological), By Regional Outlook and Forecast, 2022 – 2028

Global Insomnia Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Hospital, Retail, and Others), By Therapy Type (Pharmacological and Non-Pharmacological), By Regional Outlook and Forecast, 2022 – 2028

The Global Insomnia Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period.

A common sleep disorder called insomnia can make it difficult to fall asleep, stay asleep, or wake up early and have trouble falling back asleep. Stress, bad sleeping habits, irregular sleep schedules, mental health conditions like physical illnesses and pain, anxiety and depression, medications, neurological issues, and specific sleep disorders are some of the common causes of insomnia.

The rise in the prevalence of distinct sleep disorders, including parasomnias as well as insomnia, and the rise in mental depression and other painful conditions, are the main factors driving the growth of the insomnia market size. Sleep issues are a result of mental depression. As a result, an increase in mental depression among the general population contributes to the growth of the insomnia market. Furthermore, taking some medications for a chronic condition over an extended period of time has some side effects that are thought to impair a patient's ability to sleep.

Additionally, the market for insomnia is expanding due to an increase in work-related stress. The increased workload and demanding work schedules result in poor sleep. Additionally, a lot of people including security guards work odd shifts, and the manufacturing sector is open around-the-clock. The quality and rhythm of sleep are impacted by these irregular work shifts. Also, a rise in the number of sleep diagnostics and centres for people with insomnia helps has been seen in the past few years. The centres for insomnia help people get better quality sleep, and the centres for sleep disorders are utilized as diagnostic testing facilities.

COVID-19 Impact Analysis

It is anticipated that the COVID-19 outbreak will benefit the expansion of the market for insomniac remedies. Due to improperly functioning industries brought on by the COVID-19 pandemic, many workers lost their jobs, which contributed to an increase in stress levels in society. Additionally, some people around the world developed depression as a result of pandemic fear. As a result, the COVID-19 pandemic's increased incidence of insomnia a condition marked by stress and depression boosts the demand for drugs that treat insomnia and propel the market's expansion.

Market Growth Factors

Increasing Aging Population

According to studies, older people (defined as those 65 and older) appear to have an 11-fold increased risk of developing some types of cancer than younger people. The burden of cancer among the elderly would then increase as the world population ages over the following 20 years. Refractive errors, cataracts, sleep issues, and hearing loss are all fairly common in older people. A large ratio of old age people is facing sleeping issues worldwide. Thus, the rise in the aging population would result in an increasing number of insomnia cases which would further support the growth of the insomnia market over the forecast period.

Increasing Healthcare Costs

Rising healthcare costs and earlier disease diagnosis because of greater awareness of treatment options are factors that are anticipated to fuel the market growth over the course of the forecast period. The increasing size and number of funds invested in the healthcare industry by governments of different countries are one of the primary drivers of the market's growth. Governments from a number of nations boosted their investments in creating healthcare systems whenever the COVID-19 pandemic first started to spread. As the pandemic's impact lessens, various hospitals are now concentrating on using these resources to treat other severe diseases. The insomnia market is expanding as a result of rising healthcare investment.

Market Restraining Factors

High Cost Of Diagnosing And Treating Insomnia

The high cost of diagnosis and treatment is one of the major factors impeding the growth of the insomnia market. Additionally, the term "sleeping problem" covers a wide range of illnesses that have significant detrimental effects on an individual's health and incur high societal costs. Insomnia makes it difficult to carry out daily tasks and is associated with a heavy financial & medical burden many patients are completely disabled. Insomnia patients spent about two times as much on direct medical care each year as matched controls without condition. The market for insomnia is not expanding because of the high cost of the medication.

Distribution Channel Outlook

By distribution channel, the insomnia market is divided into hospital, retail and others. The retail segment recorded a substantial revenue share in the insomnia market in 2021. The market in this segment is growing as a result of the wide availability of pills for treatment of sleeping disorder in various retail stores. In addition, the market is also growing due to rising awareness of consequences of diseases such as insomnia. Also, the government is supporting the medicines for condition to be marketed in such stores.

Therapy Type Outlook

Based on therapy type, the insomnia market is segmented into non-pharmacological therapy, pharmacological therapy. In 2021, the pharmacological therapy segment dominated the insomnia market with the maximum revenue share. This is due to the rising prevalence of insomnia and the growing number of major manufacturers of therapeutic drugs for insomnia. The presence of pills for insomnia treatment and sleeping pills is wide all over the world. The market is expanding in this segment as a result of a large number of market players present all over the world.

Regional Outlook

Region wise, the insomnia market is analyzed across the North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region held the highest revenue share in the insomnia market. This is due to an increase in the prevalence of insomnia, a high incidence of stress at work, and a developed healthcare system, including the presence of insomnia centers in the region. Additionally, a rise in the number of patients suffering from chronic renal and kidney illnesses as well as the existence of a sizable number of insomnia clinics in this region are predicted to fuel market growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.

Strategies deployed in Insomnia Market

Oct-2021: Currax expanded its geographical footprints in Brentwood by opening HQ in the region. This expansion aimed at expanding access to medicines, both generic and brand name.

Dec-2020: Vanda Pharmaceuticals got FDA approval for the HETLIOZ capsule & liquid formulation, the first FDA-approved medication for patients with SMS. The product would be used for the treatment of adults & children, respectively, with nighttime sleep disturbances associated with Smith-Magenis Syndrome (SMS).

Jun-2020: Sanofi expanded its geographical footprint in India. This expansion focused on producing Amaryl & Daonil tablets for blood glucose reduction, Frisium for seizures, and Stilnoct for insomnia in the region.

Jun-2020: Eisai launched DAYVIGO CIV, the in-house discovered orexin receptor antagonist. This launch would address adults with insomnia, characterized by difficulties with sleep onset and sleep maintenance.

Dec-2019: Eisai got FDA approval for DAYVIGO. Through this approval, DAYVIGO would be commercially available in 5 mg and 10 mg tablets following scheduling by the U.S. Drug Enforcement Administration (DEA), which is expected to occur within 90 days.

Sep-2019: Currax signed an agreement to acquire Nalpropion Pharmaceuticals, a biopharmaceutical company focused on the treatment of weight loss. This acquisition enables Currax to own the worldwide rights to CONTRAVE, one of the most prescribed weight-loss brand medications in the US.

Sep-2019: Takeda and Lundbeck got Labour and Welfare (MHLW) approval of Trintellix. By this approval, Trintellix would be able to provide the treatment of depression and depressed state.

Jul-2019: Zydus Cadila introduced Ramelteon tablets, USFDA-approved capsules used to treat insomnia. Ramelteon would be used in the treatment of insomnia associated with having trouble falling asleep.

Scope of the Study

Market Segments covered in the Report:

By Distribution Channel

  • Hospital
  • Retail
  • Others
By Therapy Type
  • Pharmacological
  • Non-Pharmacological
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
  • Eisai Co., Ltd.
  • Merck Group
  • Pfizer, Inc.
  • Vanda Pharmaceuticals, Inc.
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Sanofi S.A.
  • Viatris, Inc.
  • Takeda Pharmaceutical Company Limited
  • Purdue Pharma L.P.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Insomnia Market, by Distribution Channel
1.4.2 Global Insomnia Market, by Therapy Type
1.4.3 Global Insomnia Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Insomnia Market
Chapter 4. Global Insomnia Market by Distribution Channel
4.1 Global Hospital Market by Region
4.2 Global Retail Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Insomnia Market by Therapy Type
5.1 Global Pharmacological Market by Region
5.2 Global Non-Pharmacological Market by Region
Chapter 6. Global Insomnia Market by Region
6.1 North America Insomnia Market
6.1.1 North America Insomnia Market by Distribution Channel
6.1.1.1 North America Hospital Market by Country
6.1.1.2 North America Retail Market by Country
6.1.1.3 North America Others Market by Country
6.1.2 North America Insomnia Market by Therapy Type
6.1.2.1 North America Pharmacological Market by Country
6.1.2.2 North America Non-Pharmacological Market by Country
6.1.3 North America Insomnia Market by Country
6.1.3.1 US Insomnia Market
6.1.3.1.1 US Insomnia Market by Distribution Channel
6.1.3.1.2 US Insomnia Market by Therapy Type
6.1.3.2 Canada Insomnia Market
6.1.3.2.1 Canada Insomnia Market by Distribution Channel
6.1.3.2.2 Canada Insomnia Market by Therapy Type
6.1.3.3 Mexico Insomnia Market
6.1.3.3.1 Mexico Insomnia Market by Distribution Channel
6.1.3.3.2 Mexico Insomnia Market by Therapy Type
6.1.3.4 Rest of North America Insomnia Market
6.1.3.4.1 Rest of North America Insomnia Market by Distribution Channel
6.1.3.4.2 Rest of North America Insomnia Market by Therapy Type
6.2 Europe Insomnia Market
6.2.1 Europe Insomnia Market by Distribution Channel
6.2.1.1 Europe Hospital Market by Country
6.2.1.2 Europe Retail Market by Country
6.2.1.3 Europe Others Market by Country
6.2.2 Europe Insomnia Market by Therapy Type
6.2.2.1 Europe Pharmacological Market by Country
6.2.2.2 Europe Non-Pharmacological Market by Country
6.2.3 Europe Insomnia Market by Country
6.2.3.1 Germany Insomnia Market
6.2.3.1.1 Germany Insomnia Market by Distribution Channel
6.2.3.1.2 Germany Insomnia Market by Therapy Type
6.2.3.2 UK Insomnia Market
6.2.3.2.1 UK Insomnia Market by Distribution Channel
6.2.3.2.2 UK Insomnia Market by Therapy Type
6.2.3.3 France Insomnia Market
6.2.3.3.1 France Insomnia Market by Distribution Channel
6.2.3.3.2 France Insomnia Market by Therapy Type
6.2.3.4 Russia Insomnia Market
6.2.3.4.1 Russia Insomnia Market by Distribution Channel
6.2.3.4.2 Russia Insomnia Market by Therapy Type
6.2.3.5 Spain Insomnia Market
6.2.3.5.1 Spain Insomnia Market by Distribution Channel
6.2.3.5.2 Spain Insomnia Market by Therapy Type
6.2.3.6 Italy Insomnia Market
6.2.3.6.1 Italy Insomnia Market by Distribution Channel
6.2.3.6.2 Italy Insomnia Market by Therapy Type
6.2.3.7 Rest of Europe Insomnia Market
6.2.3.7.1 Rest of Europe Insomnia Market by Distribution Channel
6.2.3.7.2 Rest of Europe Insomnia Market by Therapy Type
6.3 Asia Pacific Insomnia Market
6.3.1 Asia Pacific Insomnia Market by Distribution Channel
6.3.1.1 Asia Pacific Hospital Market by Country
6.3.1.2 Asia Pacific Retail Market by Country
6.3.1.3 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Insomnia Market by Therapy Type
6.3.2.1 Asia Pacific Pharmacological Market by Country
6.3.2.2 Asia Pacific Non-Pharmacological Market by Country
6.3.3 Asia Pacific Insomnia Market by Country
6.3.3.1 China Insomnia Market
6.3.3.1.1 China Insomnia Market by Distribution Channel
6.3.3.1.2 China Insomnia Market by Therapy Type
6.3.3.2 Japan Insomnia Market
6.3.3.2.1 Japan Insomnia Market by Distribution Channel
6.3.3.2.2 Japan Insomnia Market by Therapy Type
6.3.3.3 India Insomnia Market
6.3.3.3.1 India Insomnia Market by Distribution Channel
6.3.3.3.2 India Insomnia Market by Therapy Type
6.3.3.4 South Korea Insomnia Market
6.3.3.4.1 South Korea Insomnia Market by Distribution Channel
6.3.3.4.2 South Korea Insomnia Market by Therapy Type
6.3.3.5 Singapore Insomnia Market
6.3.3.5.1 Singapore Insomnia Market by Distribution Channel
6.3.3.5.2 Singapore Insomnia Market by Therapy Type
6.3.3.6 Malaysia Insomnia Market
6.3.3.6.1 Malaysia Insomnia Market by Distribution Channel
6.3.3.6.2 Malaysia Insomnia Market by Therapy Type
6.3.3.7 Rest of Asia Pacific Insomnia Market
6.3.3.7.1 Rest of Asia Pacific Insomnia Market by Distribution Channel
6.3.3.7.2 Rest of Asia Pacific Insomnia Market by Therapy Type
6.4 LAMEA Insomnia Market
6.4.1 LAMEA Insomnia Market by Distribution Channel
6.4.1.1 LAMEA Hospital Market by Country
6.4.1.2 LAMEA Retail Market by Country
6.4.1.3 LAMEA Others Market by Country
6.4.2 LAMEA Insomnia Market by Therapy Type
6.4.2.1 LAMEA Pharmacological Market by Country
6.4.2.2 LAMEA Non-Pharmacological Market by Country
6.4.3 LAMEA Insomnia Market by Country
6.4.3.1 Brazil Insomnia Market
6.4.3.1.1 Brazil Insomnia Market by Distribution Channel
6.4.3.1.2 Brazil Insomnia Market by Therapy Type
6.4.3.2 Argentina Insomnia Market
6.4.3.2.1 Argentina Insomnia Market by Distribution Channel
6.4.3.2.2 Argentina Insomnia Market by Therapy Type
6.4.3.3 UAE Insomnia Market
6.4.3.3.1 UAE Insomnia Market by Distribution Channel
6.4.3.3.2 UAE Insomnia Market by Therapy Type
6.4.3.4 Saudi Arabia Insomnia Market
6.4.3.4.1 Saudi Arabia Insomnia Market by Distribution Channel
6.4.3.4.2 Saudi Arabia Insomnia Market by Therapy Type
6.4.3.5 South Africa Insomnia Market
6.4.3.5.1 South Africa Insomnia Market by Distribution Channel
6.4.3.5.2 South Africa Insomnia Market by Therapy Type
6.4.3.6 Nigeria Insomnia Market
6.4.3.6.1 Nigeria Insomnia Market by Distribution Channel
6.4.3.6.2 Nigeria Insomnia Market by Therapy Type
6.4.3.7 Rest of LAMEA Insomnia Market
6.4.3.7.1 Rest of LAMEA Insomnia Market by Distribution Channel
6.4.3.7.2 Rest of LAMEA Insomnia Market by Therapy Type
Chapter 7. Company Profiles
7.1 Eisai Co., Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Product Launches and Product Expansions:
7.1.5.2 Approvals and Trails:
7.2 Takeda Pharmaceutical Company Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Approvals and Trails:
7.3 Vanda Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.3.4 Recent strategies and developments:
7.3.4.1 Approval and Trails:
7.4 Cadila Healthcare Ltd. (Zydus Cadila)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Sanofi S.A.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Geographical Expansions:
7.6 Merck Group
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Acquisition and Mergers:
7.9.2.2 Geographical Expansions:
7.10. Purdue Pharma L.P.
7.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings